Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338056
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(156,998) | $(147,440) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 864 | 2,210 |
| Stock compensation expense | 19,716 | 33,825 |
| Impairment of intangible asset | — | 2,300 |
| Loss on disposal of property and equipment | — | 615 |
| Net amortization of premiums and discounts on investments | (1,406) | (2,991) |
Item 1. Financial Statements.
FAQ
- What is Relay Therapeutics, Inc.'s D&A?
- Relay Therapeutics, Inc. (RLAY) reported D&A of $360K in Q2 2026.
- How has Relay Therapeutics, Inc.'s D&A changed year-over-year?
- Relay Therapeutics, Inc.'s D&A decreased by 64.1% year-over-year, from $1M to $360K.
- What is the long-term trend for Relay Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s D&A has grown at a -2.4% compound annual growth rate (CAGR), from $3.93M to $3.56M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Relay Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude